Alexion Pharmaceuticals Inc (ALXN)

156.70 +0.05  +0.03% NASDAQ Jan 15, 20:00 USD
View Full Chart
Price Chart
View All ALXN News

News

View All Events

Events

Date Type Description
01/29/2021 Earnings Alexion Pharmaceuticals Inc Fourth Quarter Earnings for 2020 Release
01/29/2021 08:00 EST Misc Alexion Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 2020
10/29/2020 Earnings Alexion Pharmaceuticals Inc Third Quarter Earnings Result for 2020
10/29/2020 08:00 EDT Misc Alexion Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2020
07/30/2020 08:00 EDT Misc Alexion Pharmaceuticals Inc Second Quarter Earnings Conference Call for 2020
07/30/2020 Earnings Alexion Pharmaceuticals Inc Second Quarter Earnings Result for 2020
05/13/2020 17:30 EDT Misc Alexion Pharmaceuticals Inc Annual General Meeting for 2019
05/06/2020 08:00 EDT Misc Alexion Pharmaceuticals Inc First Quarter Earnings Conference Call for 2020
05/06/2020 Earnings Alexion Pharmaceuticals Inc First Quarter Earnings Result for 2020
02/04/2020 Misc Alexion Pharmaceuticals Inc Annual Report for 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.alexion.com
  • Investor Relations URL: http://ir.alexionpharm.com/
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Blend
  • Next Earnings Release: Jan. 29, 2021
  • Last Earnings Release: Oct. 29, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.

Top Fund Holders

Symbol Name Weighting
BBH VanEck Vectors Biotech ETF 5.56%
MNA IQ Merger Arbitrage ETF 5.20%
FIJYX Fidelity Advisor® Biotechnology Z 4.25%
FBT First Trust NYSE Arca Biotech ETF 3.83%
URLGX Columbia Select Large Cap Growth R 3.41%
IBB iShares Nasdaq Biotechnology ETF 2.72%
LMVRX ClearBridge Value R 2.18%
FRBRX Franklin Biotechnology Discovery R6 2.12%
THISX T. Rowe Price Health Sciences I 1.26%
XBI SPDR® S&P Biotech ETF 1.09%
FVLKX Fidelity® Value K 0.97%
RSP Invesco S&P 500® Equal Weight ETF 0.25%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.